Premium
Promise of chemokine network‐targeted nanoparticles in combination nucleic acid therapies of metastatic cancer
Author(s) -
Xie Ying,
Wang Yazhe,
Li Jing,
Hang Yu,
Oupický David
Publication year - 2018
Publication title -
wiley interdisciplinary reviews: nanomedicine and nanobiotechnology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.175
H-Index - 72
eISSN - 1939-0041
pISSN - 1939-5116
DOI - 10.1002/wnan.1528
Subject(s) - nanomedicine , small interfering rna , gene silencing , microrna , rna interference , chemokine receptor , chemokine , cancer , metastasis , biology , cancer research , medicine , computational biology , rna , immunology , nanotechnology , immune system , gene , materials science , biochemistry , nanoparticle
Chemokines and chemokine receptors play key roles in cancer progression and metastasis. Although multiple chemokines and chemokine receptors have been investigated, inhibition of CXCR4 emerged as one of the most promising approaches in combination cancer therapy, especially when focused on the metastatic disease. Small RNA molecules, such as small interfering RNA (siRNA) and microRNA (miRNA), represent new class of therapeutics for cancer treatment through RNA interference‐mediated gene silencing. However, the clinical applicability of siRNA and miRNA is severely limited by the lack of effective delivery systems. There is a significant therapeutic potential for CXCR4‐targeted nanomedicines in combination with the delivery of siRNA and miRNA in cancer. Recently developed CXCR4‐targeted polymeric drugs and nanomedicines, including cyclam‐ and chloroquine‐based polymeric CXCR4 antagonists are introduced here and their ability to deliver functional siRNA and miRNA is discussed. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Nanotechnology Approaches to Biology > Nanoscale Systems in Biology